About the Company
We do not have any company description for Equillium, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EQ News
Interview with the Co-Founder and CEO: Equillium Inc. (NASDAQ:EQ)
It’s been a few years since you last spoke with The Wall Street Transcript. Can you provide a refresher on the history and overview of the company? Mr. Steel: Sure. So we started Equillium back in ...
Equillium, Inc. (EQ)
LA JOLLA, Calif., April 01, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory ...
Buy Rating Affirmed for Equillium Amid Promising Clinical Trials and Potential Financial Upsides
Begin your TipRanks Premium journey today. Equillium (EQ) Company Description: Equillium, Inc. is a biotechnology company, which engages in the development of products for severe immuno ...
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory ...
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced positive topline ...
Biotech Rallies Strongly On Second Consecutive Positive Headline
Shares of Equillium Inc. (Nasdaq:EQ) rallied strongly on Tuesday, with traders pushing shares of the micro cap up to $2.296/share (+8.82%) at the early session high. Equillium Inc is a ...
Equillium, Inc. (EQ) interactive stock chart – Yahoo Finance
LA JOLLA, Calif., April 01, 2024--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, ...
Equillium, Inc. (EQ)
Overall score is calculated based on proprietary scores based on sector averages in key company indicators: fair value, dividends, innovation, hiring, and insider sentiment. Note: if you don't see ...
Equillium Reports on Fourth Quarter and Full Year 2023 Financial Results and Corporate and Clinical Highlights
meetings Ono Pharmaceutical option exercise decision for itolizumab expected in 2H 2024 Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of ...
Loading the latest forecasts...